Recruiting | Phase II/III
A Randomized Phase II/III Study of Conventional Chemotherapy +/- Uproleselan (GMI-1271) in Older Adults with Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy
To compare the usual treatment alone to using uproleselan plus the usual treatment.
- Group 1: Daunorubicin + Cytarabine (usual approach group)
- Group 2: Daunorubicin + Cytarabine + Uproleselan (study drug)
Patients will either get the usual treatment or the usual treatment plus the study drug for up to 5 months. After treatment is finished the doctor will continue to follow up and watch for side effects for up to 5 years.
Key Participation Requirements:
Male or Female
60 years and older
Acute Myeloid Leukemia
No prior chemotherapy for MDS or AML
Patients must sign an approved informed consent and authorization permitting release of personal health information.
Methodist Health System Trial Code:
For more information, visit the U.S. National Library of Medicine clinical trial database.